LogicBio Therapeutics (NASDAQ: LOGC) is one of 114 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare LogicBio Therapeutics to similar businesses based on the strength of its earnings, risk, dividends, institutional ownership, valuation, analyst recommendations and profitability.
Institutional and Insider Ownership
56.5% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 48.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 43.5% of LogicBio Therapeutics shares are owned by company insiders. Comparatively, 16.4% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a breakdown of current ratings and price targets for LogicBio Therapeutics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|LogicBio Therapeutics Competitors||837||2781||6069||261||2.58|
LogicBio Therapeutics currently has a consensus price target of $23.33, suggesting a potential upside of 92.04%. As a group, “Biological products, except diagnostic” companies have a potential upside of 39.60%. Given LogicBio Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe LogicBio Therapeutics is more favorable than its rivals.
This table compares LogicBio Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|LogicBio Therapeutics Competitors||-5,144.22%||-64.24%||-27.96%|
Valuation and Earnings
This table compares LogicBio Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|LogicBio Therapeutics||N/A||-$17.62 million||-4.00|
|LogicBio Therapeutics Competitors||$897.64 million||$190.37 million||-1.26|
LogicBio Therapeutics’ rivals have higher revenue and earnings than LogicBio Therapeutics. LogicBio Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
LogicBio Therapeutics beats its rivals on 8 of the 12 factors compared.
LogicBio Therapeutics Company Profile
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 that is been developed for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. LogicBio Therapeutics, Inc. has a partnership with Children's Medical Research Institute (CMRI) of Australia to develop new viral vectors. The company was founded in 2014 and is based in Cambridge, Massachusetts.
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.